Cancer Drug Resistance

cdr

Search

Hot Keywords

Drug Resistance Mechanisms Epigenetic Resistance in Cancer Therapy Biomarkers Pharmacogenetics of Cancer Liquid Biopsy Targeted Cancer Therapy Non-coding RNAs Kinase Inhibitors ABC Transporters

Nanocarrier drug resistant tumor interactions: novel approaches to fight drug resistance in cancer

Aleksandra Benko, ... Thomas J. Webster

Review|Published on: 7 Jan 2021
How to win the ovarian cancer stem cell battle: destroying the roots

Akimasa Takahashi, ... Ilana Chefetz

Review|Published on: 22 Dec 2020

Submit a Manuscript

Original Articles See more

Liposome co-encapsulation of anti-cancer agents for pharmacological optimization of nanomedicine-based combination chemotherapy

Alberto Gabizon, ... Hilary Shmeeda

Published on: 22 Dec 2020

Characterization of acquired nutlin-3 resistant non-small cell lung cancer cells

Christophe Deben, ... Patrick Pauwels

Published on: 5 Dec 2020
Evaluation of the reducing potential of PSMA-containing endosomes by FRET imaging

Chelvam Venkatesh, ... Philip S. Low

Published on: 26 Nov 2020
Albumin nanoformulations as an innovative solution to overcome doxorubicin chemoresistance

Federica Bessone, ... Roberta Cavalli

Published on: 13 Nov 2020
A bendamustine resistance gene signature in diffuse large B-cell lymphoma and multiple myeloma

Issa Ismail Issa, ... Karen Dybkær

video

Published on: 26 Nov 2020

EGFR signaling promotes resistance to CHK1 inhibitor prexasertib in triple negative breast cancer

Kevin J. Lee, ... Natalie R. Gassman

Published on: 5 Dec 2020
Albumin nanoformulations as an innovative solution to overcome doxorubicin chemoresistance

Federica Bessone, ... Roberta Cavalli

Published on: 13 Nov 2020
Dichloroacetate enhances the antitumor effect of pirarubicin via regulating the ROS-JNK signaling pathway in liver cancer cells

Xiao-Jing Yan, ... Ji-Qin Lian

Published on: 4 Sep 2020

MEK inhibition activates STAT signaling to increase breast cancer immunogenicity via MHC-I expression

Derek A. Franklin, ... Justin M. Balko

Published on: 25 Apr 2020
Quantitative analysis of taxane drug target engagement of microtubules in circulating tumor cells from metastatic castration resistant prostate cancer patients treated with CRXL301, a nanoparticle of docetaxel

Eiman Mukhtar, ... Paraskevi Giannakakou

Published on: 17 Apr 2020

Review Articles See more

The role of extracellular vesicles in acquisition of resistance to therapy in glioblastomas

Anudeep Yekula, ... Leonora Balaj

Published on: 13 Nov 2020
Cell-mediated and cell membrane-coated nanoparticles for drug delivery and cancer therapy

Serkan Yaman, ... Kytai T. Nguyen

Published on: 3 Nov 2020
3,3’-Diindolylmethane and its derivatives: nature-inspired strategies tackling drug resistant tumors by regulation of signal transduction, transcription factors and microRNAs

Bernhard Biersack

Published on: 12 Oct 2020
Attempts to remodel the pathways of gemcitabine metabolism: Recent approaches to overcoming tumours with acquired chemoresistance

Yuriko Saiki, ... Akira Horii

Published on: 12 Oct 2020

Natural products as a means of overcoming cisplatin chemoresistance in bladder cancer

Ganeshkumar Rajendran, ... Benjamin L. Woolbright

Published on: 5 Dec 2020
Key genes and drug delivery systems to improve the efficiency of chemotherapy

Zally Torres-Martinez, ... Kai Griebenow

Published on: 7 Jan 2021
P53-regulated autophagy and its impact on drug resistance and cell fate

Daeun Shim, ... Carl G. Maki

Published on: 5 Dec 2020
Perspectives of nano-carrier drug delivery systems to overcome cancer drug resistance in the clinics

Anna Ulldemolins, ... Simo Schwartz Jr

video

Published on: 5 Dec 2020

Others See more

UCP2 - Taking the heat out of P-glycoprotein?

Richard Callaghan, Mary Board

Opinion|Published on: 8 Jan 2021

Overcoming drug resistance in glioblastoma: new options in sight?

Joanna Kopecka, Chiara Riganti

Editorial|Published on: 13 Jan 2021
Application of liquid biopsy for prognostic status of cancers and drug response

Dario Marchetti

Editorial|Published on: 3 Nov 2020
Aberrant DNA repair as a potential contributor for the clonal evolution in subsets of anaplastic thyroid carcinomas arising through dedifferentiation: implications for future therapeutic algorithms?

Carl Christofer Juhlin

Commentary|Published on: 3 Nov 2020
Can HIPEC be used against platinum-resistance and for inducing sensitivity to PARP inhibitors in ovarian cancer?

Thales Paulo Batista, Graziela Zibetti Dal Molin

video

Commentary|Published on: 10 Jul 2020

Most Cited Papers In Last Two Years See more

How to overcome ATP-binding cassette drug efflux transporter-mediated drug resistance?

Adrian C. Jaramillo, ... Godefridus J. Peters

Review|Published on: 19 Mar 2018

MicroRNAs in neuroblastoma tumorigenesis, therapy resistance, and disease evolution

Natarajan Aravindan, ... Sheeja Aravindan

Review|Published on: 19 Dec 2019
Mechanisms of cisplatin sensitivity and resistance in testicular germ cell tumors

Ratnakar Singh, ... Michael J. Spinella

Review|Published on: 19 Sep 2019

Resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer

Nele Van Der Steen, ... Godefridus J. Peters

Review|Published on: 19 Dec 2018
Cancer drug resistance: a new perspective

Godefridus J. Peters

Editorial|Published on: 19 Mar 2018
Improved potency of F10 relative to 5-fluorouracil in colorectal cancer cells with p53 mutations

Anthony Dominijanni, William H. Gmeiner

Original Article|Published on: 19 Mar 2018

Ongoing Special Issues See more

Special Issue Ebooks See more

About The Journal

ISSN

2578-532X (Online)

Publisher

OAE Publishing Inc.

Article Processing Charge

OAE Publishing Inc. undertakes Article Processing Charge for authors
Editor-in-Chief

Godefridus J. Peters

Publishing Model

Gold Open Access

Copyright

Copyright is retained by authors
Publication Frequency

Quarterly

Contact Us

editorial@cdrjournal.com

Journal Data Analysis

Total publications: 200

Total article views: 533,177

Total article downloads: 74,392

Membership

COPE

Cancer Drug Resistance is a member of the Committee on Publication Ethics (COPE) and fully adhere to its Code of Conduct and to its Best Practice Guidelines.
STM

Cancer Drug Resistance (cdr) is a member of and subscribes to the principles of STM. Authors of cdr can reuse a certain quantity of article contents from the chargeable publications of other STM members for free in their submissions to cdr.
ORCID

Cancer Drug Resistance (cdr) is a member of ORCID and MESAs system has been connected with ORCID. After submissions to cdr are published, they will be automatically synchronized to the authors' ORCID accounts if the authors have connected their MESAs accounts with ORCID accounts. cdr's reviewers can choose to synchronize their review records to their ORCID accounts when filling in review reports.
Crossref

Cancer Drug Resistance is a member of Crossref, which makes research outputs easy to find, cite, link, assess, and reuse.
iThenticate

All submissions to Cancer Drug Resistance are checked for plagiarism by iThenticate.
Check for updates

All published articles in Cancer Drug Resistance are enriched with a record of the current article status.

Open Archives

Portico

All published articles will be preserved here permanently:
https://www.portico.org/

Partners